分享好友 资讯首页 频道列表

Regnology Announces Next-Generation Ascend Platform with Agentic AI, Advancing the Future of Regulatory Reporting

2026-04-01 09:4519180

Enhancements Extend to Regnology Supervisory Hub, accelerating the Straight Through Reporting (STR) vision

FRANKFURT, Germany -- (BUSINESS WIRE) --

Regnology, a global leading provider at the intersection of regulatory, risk, finance and supervisory technology, today announced the evolution of Ascend, the nextgeneration Regnology platform. This landmark release introduces a powerful agentic AI layer to the Regnology platform and formally integrates the Regnology Supervisory Hub (RSH) into the Ascend ecosystem.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330254615/en/

Launched in late 2025, Ascend is the catalyst of Regnology’s Straight-Through-Reporting (STR) vision. The initial rollout empowered financial institutions with RRH Ascend delivering intelligent data governance for proactive quality assurance, predictive insights to anticipate regulatory demands, powerful automation to execute complex workflows, and contextual collaboration for seamless human oversight.

“Our position at the nexus of risk, regulation, and finance gives Regnology a unique vantage point to support the industry’s evolution,” said Rob Mackay, CEO of Regnology. “Our nextgen Ascend platform is the engine of a paradigm shift transforming compliance into a single strategic command center where highquality data, continuous insight, and intelligent orchestration converge.”

With the new AI-agentic orchestration layer, Ascend transforms regulatory reporting and financial oversight into adaptive, intelligent, and automated processes. Built on Regnology’s unified RGD data foundation, AI agents embedded within the Regnology platform will continuously manage workflows, analyze regulatory data and generate advanced and contextually accurate insights. Operating on a consistent, highquality data model, enables these agents to strengthen both institutional reporting and supervisory understanding.

The Ascend platform now supercharges RSH across the entire oversight lifecycle. Workflow agents automate data collection, validation, and examinations, while realtime analytics agents surface critical Key Risk Indicators (KRIs) and interpret everything from granular indicators to narrative reports. By consolidating these capabilities on a trusted unified platform that operationalizes STR, RSH Ascend enables a more autonomous supervisory operating model delivering faster oversight cycles, higher efficiency, and significantly stronger risk anticipation.

“Ascend was designed as the foundation for a new era of regulatory reporting —bringing automation, transparency, and intelligence to the core of the financial operating model,” said Linda Middleditch, Chief Product Officer at Regnology. “By extending agentic AI to both regulators and the regulated on a trusted RGD data backbone, we empower the industry to move from reactive reporting to continuous intelligence for faster decisions and more resilient oversight.”

Regnology will progressively onboard all its entire solution offering to the agentic-AI enabled Ascend platform, helping accelerate the industry’s transition toward full realization of the STR vision.

About Regnology

Regnology is a recognized leader in regulatory, risk, tax, and finance reporting technology— connecting regulators and the regulated across more than 100 countries. Our unique position enables us to span the full spectrum of industry needs, delivering solutions that address both oversight and compliance requirements to a broad range of clients, including global Tier 1 banks, local and regional institutions, corporates, insurers, and authorities.

With presence in over 30 countries and deep local expertise, Regnology combines a truly global approach with an understanding of regional regulatory requirements. Our unified data model and “map once, report many” methodology ensure consistency, auditability, and scalability across jurisdictions, while our modular, cloud-native solutions empower clients to achieve compliance, unlock enterprise-wide insights, and future-proof their operations.

Regnology’s leadership is underpinned by fast-paced growth and a front-running approach to innovation, continually investing in automation, AI, and domain expertise to deliver future-ready solutions.

For more information about Regnology, connect with us on LinkedIn.

Visit our website: www.regnology.net.

CONTACT:

Mireille Adebiyi – Chief Marketing Officer
Email: mireille.adebiyi@regnology.net

反对 0
举报 0
收藏 0
打赏 0
评论 0
Philip Morris International Presents its Value Report 2025: change in motion
The company’s annual disclosure unveils its Value Plan 2030+ STAMFORD, CT--(BUSINESS WIRE)--Philip Morris International (NYSE: PM) today released its Value Report 2025, offering a holistic perspective on the company’s approach...

0评论2026-04-011267

Lotte Rental Speeds Growth and Innovation with Multiyear Partnership with Rimini Street
South Korea’s top car rental company cuts IT costs, boosts flexibility and powers digital transformation with long-term savings and robust services powered by Rimini Support for SAP and Oracle LAS VEGAS--(BUSINESS WIRE)--Rimini Street, Inc. (Na...

0评论2026-04-011339

印度:快速崛起的太阳能新兴市场
德国慕尼黑及普福尔茨海姆--(美国商业资讯)--全球太阳能产业正处于快速扩张阶段。其中,印度在政府资金支持、税收激励、补贴政策以及银行绿色贷款等多重因素推动下,增长尤为显著。2025年,印度新增太阳能装机容量达37.5吉瓦,同比增长50%。根据2026年财政预算,预计新增装机规模将达到45至50吉瓦,这将推动这一全球人口最多的国家跃升为全球第二大太阳能市场。2026年6月23日至25日,Intersolar Europe将在德国慕尼黑举行,届时将重点聚焦印度市场。作为全球光伏产业的重要新兴市...

0评论2026-04-011967

Rubedo Life Sciences宣布其核心候选药物RLS-1496在斑块型银屑病、特应性皮炎及皮肤衰老患者中的一期临床试验取得积极初步结果
作为首个进入人体临床试验的GPX4(选择性谷胱甘肽过氧化物酶4)调节剂,RLS-1496的一期研究已达到主要终点,并在银屑病与特应性皮炎中显示出靶点作用与临床疗效改善之间具有统计学显著相关性 RLS-1496采用首创的疾病修饰机制,通过靶向驱动“炎性衰老”(inflammaging)及多种年龄相关慢性退行性疾病的病理性衰老细胞发挥作用 RLS-1496的第二项临床研究——针对日光性角化病(癌前皮肤病变)的1b/2a期试验——正在美国开展,预计将于今年晚些时候完成 Rubedo首席执...

0评论2026-04-011268

百奥赛图与大正制药达成RenNano全人仅重链抗体发现平台授权协议
中国北京和日本东京--(美国商业资讯)--百奥赛图(北京)医药科技股份有限公司(以下简称“百奥赛图”,SSE: 688796;HKEX: 02315),一家以创新技术驱动新药研发的国际性生物技术公司,今日宣布与大正制药株式会社(以下简称“大正制药”)达成一项平台授权协议。百奥赛图授予大正制药其专有的RenNano®全人仅重链抗体(HCAb)发现平台的使用权,以支持大正制药的内部新药研发项目。 根据协议条款,大正制药将利用RenNan...

0评论2026-04-011270

HistoSonics完成首批患者治疗,以评估Edison组织碎化系统在治疗良性前列腺增生(BPH)中的应用
明尼阿波利斯--(美国商业资讯)-- Edison®组织碎化系统及新型组织碎化治疗平台的开发商HistoSonics今日宣布,在香港威尔斯亲王医院(香港中文大学附属教学医院)开展的前瞻性可行性试验“WOLVERINE”中,已成功对首批患者进行了治疗。该试验旨在评估Edison®组织碎化系统治疗良性前列腺增生(BPH)的疗效。Edison系统是一种新型、非侵入性的影像引导平台,利用聚焦超声的机械特性(即组织碎化术)来破坏不需要的组织,无需侵入性手术,且与...

0评论2026-04-011688

Axelspace 太空公司牵头联合体入选日本太空战略基金项目 “提升下一代地球观测卫星能力技术”
—— 通过卫星星座与航空器开展特定排放源二氧化碳排放与吸收监测,打造气候解决方案,开拓全新市场机遇 东京--(美国商业资讯)-- Axelspace 太空公司、明星电气株式会社、全日空控股株式会社及 JIJ 株式会社联合宣布,各方共同申报的技术研发项目成功入选日本宇宙航空研究开发机构 (JAXA) 太空战略基金,项目主题为 “提升下一代地球观测卫星能力技术”。 本新闻稿包含多媒体。此处查看新闻稿全文: https://www.businesswire.com/new...

0评论2026-04-011857

超级障碍马术联赛(PJL)正式启动,设立创纪录的3亿美元保底奖金池,开启障碍马术运动新纪元
PJL助力骑手以全职职业运动员身份参赛,同时为这项运动构建可持续的经济模式。 PJL由McCourt Global支持,核心管理团队拥有数十年马术赛事、体育和娱乐行业经验,为顶级障碍马术赛事树立全新、可持续且具备全球影响力的标准。 2027年3月首个赛季开赛时,将有16支队伍在欧洲、北美和中东的14座标志性国际场馆展开角逐。 伦敦--(美国商业资讯)--超级障碍马术联赛(PJL)正式启动,赛事设立创纪录的3亿美元保底奖金池,开启障碍马术运动的新纪元。 本新闻稿包含多媒体。此处查看...

0评论2026-04-011489

Yubico任命Poupak Modirassari Enbom为首席营销官,加速全球发展势头并巩固市场领先地位
加州圣克拉拉和斯德哥尔摩--(美国商业资讯)--全球安全性最高的通行密钥开发者、硬件认证安全密钥领先供应商Yubico (NASDAQ STOCKHOLM: YUBICO)今日宣布任命Poupak Enbom为首席营销官(CMO)。 本新闻稿包含多媒体。此处查看新闻稿全文: https://www.businesswire.com/news/home/20260330359576/zh-CN/ Enbom加入Yubico正值全球各类组织在AI时代加速向抗钓鱼攻击认证和现代身份安全转型...

0评论2026-04-011665

百奥赛图合作伙伴NEOK Bio双抗ADC NEOK002获FDA IND许可,合作迈入关键里程碑
中国北京--(美国商业资讯)--百奥赛图(北京)医药科技股份有限公司(以下简称“百奥赛图”,SSE: 688796;HKEX: 02315),一家以创新技术驱动新药研发的国际性生物技术公司,今日宣布其合作伙伴NEOK Bio, Inc.近日获得美国食品药品监督管理局(FDA)对其在研新药NEOK002的新药临床试验申请(IND)批准。NEOK002是一款靶向EGFR/MUC1的抗体偶联药物(ADC),拟用于实体瘤治疗。NEOK Bio计划于2026年第二季度启动I期临...

0评论2026-04-011496